Track record : past and current projects
| CELL THERAPY | |
|---|---|
|
Pre-clinical assessment of pluripotent stem cell therapy for Huntington’s disease | |
|
COORDINATION |
A. Perrier (BIRD) |
|
PARTNERS |
P. Hantraye (CEA), David Sourdive (Cellectis) |
|
FOUNDING |
ANR RFSC 2011-2014 & NeuroStemCell FP7 project |
|
COORDINATION |
A. Rosser |
|
PARTNERS |
A.Perrier (BIRD), P. Hantraye (CEA), A. Bachoud-Levi (UPEC) |
|
FOUNDING |
Repair-HD FP7 project (En cours) |
|
COORDINATION |
AC Bachoud-Lévi (UPEC) |
|
PARTNERS |
S. Palfi (APHP), P. Remy (UPEC), P. Maison, P. Hantraye (CEA), M. Peschanski (BIRD) |
|
FOUNDING |
DRCD AP-HP, PHRC 2000, 2004, 2011 (2001–2014) |
|
Hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy | |
|
COORDINATION |
P. Aubourg and N. Cartier (Inserm) |
|
PARTNERS |
M. Cavazzana-Calvo, S Hacein-Bey-Abina, A. Fischer (Necker-Enfants Malades, Paris), C. van Kalle, M. Schmidt, A (DKFZ, Heidelberg) |
|
FOUNDING |
Inserm, AP-HP, University Paris-Descartes, ELA, AFM, Bluebirdbio (2006 – ongoing) |
|
Hematopoietic stem cell gene therapy with lentiviral vector in RETT syndrome | |
|
COORDINATION |
N. Cartier, P Aubourg (Inserm) |
|
PARTNERS |
Eithan Galun (Goldyne Savad Institute of Gene Therapy, Hadassah, Israel) |
|
FOUNDING |
Inserm, AFM |
|
GENE THERAPY | |
|---|---|
|
COORDINATION |
P. Aubourg (Inserm) |
|
PARTNERS |
R. Crystal (Cornell University, USA), Ph.Moullier, L.Hertz-Panier (CEA) |
|
FOUNDING |
ELA foundation, AP-HP, University Paris Descartes, Inserm (2012– 2016) |
|
COORDINATION |
Nathalie Cartier |
|
PARTNERS |
L. Buée (Inserm U837), O. Laprevote (Fac. Paris-Descartes), B. Delatour, Ch. Duyckaerts, Ph. Hantraye |
|
FOUNDING |
ANR-Canada, France Alzheimer, Fondation Del Ducca (2010 – 2014) |
|
Targeting therapeutic genes to oligodendrocytes in brain and spinal cord | |
|
COORDINATION |
C. Sevin, P. Aubourg (Inserm) |
|
PARTNERS |
M-A Colle (Inserm/INRA) |
|
FOUNDING |
Fondation Del Ducca (2011 – 2013) |
|
COORDINATION |
G. Bonvento (CEA), AC Bachoud-Lévi (UPEC) |
|
PARTNERS |
P. Hantraye (CEA), P. Remy (UPEC) and S. Palfi (APHP) |
|
FOUNDING |
APHP, DRCD 2000 and now submitted to the AFM (2011–2014) |
|
COORDINATION |
M-A. Colle (INRA) |
|
PARTNERS |
P. Aubourg (Inserm) |
|
FOUNDING |
AFM (under evaluation) |
|
PROSAVIN Dopamine gene based treatment for Parkinson's disease | |
| COORDINATION | S.Palfi (APHP) |
| PARTENAIRES | CEA/ APHP/ UPEC |
| FOUNDING | Oxford Biomedica (2003-2023) |
| COORDINATION | S.Palfi (APHP) |
| PARTNERS | Ph. Hantraye (CEA) |
| FOUNDING | ANR (2014-2017) |
| MODELS and BIOMARKERS | |
|---|---|
|
COORDINATION |
J. Valette |
|
PARTNERS |
|
|
FOUNDING |
Eli Lilly (2009) |
|
Development & characterization of a primate model of periventricular leucomalasia | |
|
COORDINATION |
F. La Chapelle (Inserm) |
|
PARTNERS |
P. Gressens (Inserm), L. Hertz-Pannier (CEA) |
|
FOUNDING |
INSERM-CEA (2009-2015) |
|
Imaging CNS demyelination and remyelination in Multiple Sclerosis using PET | |
|
COORDINATION |
Bruno Stankoff (IHU-A-ICM) |
|
PARTNERS |
M. Bottlaender (CEA) |
|
FOUNDING |
ELA, INSERM-DHOS, FRM, JNLF (2009-2012) |
|
COORDINATION |
P. Rémy (UPEC) |
|
PARTNERS |
P. Rémy P. Hantraye (CEA), M. Vidailhet & A. Brice (IHU) |
|
FOUNDING |
France-Parkinson (2011–2013) |
|
COORDINATION |
E. Brouillet (CEA) |
|
PARTNERS |
F. Mochel (IHU-A-ICM) |
|
FOUNDING |
ANR (2015-2018) |
|
COORDINATION |
P.Hantraye (CEA) |
|
PARTNERS |
Luc Buee (Inserm, Lille) |
|
FOUNDING |
Fondation Plan Alzheimer (2011-2013) |
|
A primate model of Huntington’s disease and the assessment of Si-RNA therapy | |
|
COORDINATION |
N. Deglon (CHUV, Lausanne, Switzerland) |
|
PARTNERS |
I2BM ET UPEC |
|
FOUNDING |
CEA/CHUV |
|
ASTROinAD : Towards a gene therapy targeting astrocytes in AD | |
| COORDINATION | G. Bonvento (CEA) |
| PARTNERS | Bruno Cauli (IHU-A-ICM), Stéphane Oliet (Inserm U682) |
| FOUNDING | Association France Alzheimer- Fondation de France |
|
COORDINATION |
E. Brouillet (CEA) |
| PARTNERS | |
| FOUNDING | Fondation de France (2011-2013) |
|
LRRK2 and alpha-synucléine : Fonctionnal interaction between LRRK2 and in vivo alpha-synucléine | |
| COORDINATION | E. Brouillet (CEA) |
| PARTNERS | |
| FOUNDING | Fondation de France (2012-2016) |
| COORDINATION | M. Dhenain (CEA) |
| PARTNERS | F. Pifferi, UMR 8571 Brunoy |
| FOUNDING | France-Alzheimer (2012-2015) |
| COORDINATION | P. Lafaye (Institut Pasteur) |
| PARTNERS | M. Dhenain (CEA), B. Delatour (IHU), S; Bay (Institut Pasteur) |
| FOUNDING | Institut Roche de Rechecrhe et Médecine Translationnelle (2011-2014) |
| DRUG BASED THERAPIES | |
|---|---|
|
COORDINATION |
M. Vidailhet (IHU) & C. Poupon (CEA) |
|
PARTNERS |
CEA, APHP, INSERM, INRIA |
|
FOUNDING |
ANR, ENP, France Parkinson, APHP, INSERM |
|
LRRK2 prospective cohort: identifying pre-symptomatic markers in Parkinson’s | |
|
COORDINATION |
A Brice (IHU) |
|
PARTNERS |
P. Remy (UPEC), P. Hantraye (CEA), MJFF, AP-HP |
|
FOUNDING |
APHP – INSERM - MJFF (2009-2014)- Fondation Avenir |
|
COORDINATION |
E. Brouillet (CEA) |
|
PARTNERS |
|
|
FOUNDING |
Servier (2012-2014) |
|
SCREENTOX:Stem Cells for Replicable Efficient Extended and Normalized Toxicology | |
|
COORDINATION |
M. Peschanski |
|
PARTNERS |
European Network (13 partners in 5 countries) |
|
FOUNDING |
EC (2011-2015) |
|
COORDINATION |
R. Aron Badin (CEA) |
|
PARTNERS |
|
|
FOUNDING |
Servier (2012-2013) |
| PEDIATRY | |
|---|---|
|
COORDINATION |
P. Gressens |
|
PARTNERS |
Inserm |
|
FOUNDING |
FP7 (2010 – 2013), Leducq Foundation (2010-2014) |
|
COORDINATION |
C. Chiron |
|
PARTNERS |
Gerard PONS, Vincent JULLIEN (U663) |
|
FOUNDING |
ERA-NET PRIOMEDCHILD (2011 – 2013), INSERM & APHP (2011 – 2012) |
|
In vitro study of the human blood brain barrier at pediatric age | |
|
COORDINATION |
C. Chiron |
|
PARTNERS |
G. PONS (U663) |
|
FOUNDING |
ANR (01/2010 – 12/2012) |
| COORDINATION | V. Mezger (CNRS) |
| PARTNERS | P. Gressens (Inserm UMR1141), J. Gallego (Inserm UMR1141) |
| FOUNDING | ANR Samenta (2014-2016) |
| COORDINATION | N. Glaichenhaus (Universite de Nice Sophia Antipolis) |
| PARTNERS | P. Gressens (Inserm UMR1141), R. Belzaux (APHM), M. Leboyer (Inserm UMR955) |
| FOUNDING | Projet incitatif immuno-psychiatrie ITMO IHP (2014) |
| COORDINATION | P. Gressens (Inserm UMR1141) |
| PARTNERS | P. Carmeliet (KUL, Leuven, Belgique), C. Verderio(CNR, Milan, Italie), H. Hagberg (University of Göteborg, Suède) |
| FOUNDING | ERA-NET Neuron (2015-2017) |
|
Rôle de l'inflammation périnatale dans la physiopathologie des troubles du spectre autistique | |
| COORDINATION | P. Gressens (Inserm UMR1141) |
| PARTNERS | R. Delorme (APHP) |
| FOUNDING | Fondation de France (2015-2016) |
